Increased expression of the membrane-bound CD40 ligand on peripheral CD4+ T cells in the acute phase of AQP4-IgG-seropositive neuromyelitis optica spectrum disorders

[1]  C. Tung,et al.  Tumor necrosis factor-α blockade treatment decreased CD154 (CD40-ligand) expression in rheumatoid arthritis , 2017, PloS one.

[2]  Yesheng Wei,et al.  Association study of CD154 polymorphisms and serum CD154 level with systemic lupus erythematous in Chinese population , 2017, Rheumatology International.

[3]  M. Harirchian,et al.  Soluble CD40 ligand derived from serum is not correlated with early MS. , 2017, Multiple sclerosis and related disorders.

[4]  M. Mori,et al.  Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder , 2017, Journal of Neuroimmunology.

[5]  Zhengqi Lu,et al.  Serum concentration of CD40L is elevated in inflammatory demyelinating diseases , 2016, Journal of Neuroimmunology.

[6]  S. Koo,et al.  Expression of CD154 (CD40L) on stimulated T lymphocytes in patients with idopathic thrombocytopenic purpura , 2016, Hematology.

[7]  W. Kozubski,et al.  International Journal of Molecular Sciences the Immunology of Neuromyelitis Optica—current Knowledge, Clinical Implications, Controversies and Future Perspectives , 2022 .

[8]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[9]  P. Calabresi,et al.  Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica , 2015, Acta neuropathologica communications.

[10]  X. Mariette,et al.  Upregulation of Membrane‐Bound CD40L on CD4+ T cells in Women with Primary Sjögren's Syndrome , 2014, Scandinavian journal of immunology.

[11]  Min Chen,et al.  The CD40/CD40L system: a new therapeutic target for disease. , 2013, Immunology letters.

[12]  Ghada S. Hassan,et al.  Requirement of Transmembrane Domain for CD154 Association to Lipid Rafts and Subsequent Biological Events , 2012, PloS one.

[13]  R. Stroud,et al.  Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter , 2012, Annals of neurology.

[14]  S. Spinelli,et al.  CD40 ligand (CD154) involvement in platelet transfusion reactions. , 2012, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[15]  T. Jaskowski,et al.  Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. , 2011, American journal of clinical pathology.

[16]  Y. Li,et al.  Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis , 2011, Journal of Neuroimmunology.

[17]  W. Mourad,et al.  Critical role of lipid rafts in CD154‐mediated T cell signaling , 2010, European journal of immunology.

[18]  N. Schmitz,et al.  CD40–CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells , 2009, Proceedings of the National Academy of Sciences.

[19]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[20]  R. Lapointe,et al.  Requirement of Oxidation-dependent CD40 Homodimers for CD154/CD40 Bidirectional Signaling* , 2007, Journal of Biological Chemistry.

[21]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[22]  M. Crow,et al.  Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. , 2006, Journal of autoimmunity.

[23]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[24]  M. Fujimoto,et al.  Elevated circulating CD40L concentrations in patients with systemic sclerosis. , 2004, The Journal of rheumatology.

[25]  H. Tilg,et al.  Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases , 2003, International Journal of Colorectal Disease.

[26]  Patrick André,et al.  Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.

[27]  T. Kipps,et al.  Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. , 2001, The Journal of rheumatology.

[28]  T. Morio,et al.  Characterization of soluble CD40 ligand released from human activated platelets. , 2001, Journal of medical and dental sciences.

[29]  S. Venuta,et al.  Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. , 2000, Journal of autoimmunity.

[30]  Link,et al.  Elevated CD40 Ligand Expressing Blood T‐Cell Levels in Multiple Sclerosis Are Reversed by Interferon‐Beta Treatment , 2000, Scandinavian journal of immunology.

[31]  G. Müller,et al.  Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[32]  R. Vakkalanka,et al.  Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. , 1999, Arthritis and rheumatism.

[33]  F. Lang,et al.  Evidence for a novel function of the CD40 ligand as a signalling molecule in T‐lymphocytes , 1997, FEBS letters.

[34]  J. Bonnefoy,et al.  Human Native Soluble CD40L Is a Biologically Active Trimer, Processed Inside Microsomes (*) , 1996, The Journal of Biological Chemistry.

[35]  A. Rojas-Mayorquín,et al.  Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis. , 2018, Immunobiology.

[36]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.